We have launched our fourth program as part of our Alnylam 5x15
product development strategy. ALN-APC is an RNAi therapeutic for the treatment of hemophilia, and as with our other Alnylam 5x15
programs, targets protein C, a genetically defined target, and will utilize Alnylam’s existing delivery platform.
[spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=734372" type=" "]Read our press release[/spotlight-link]
[spotlight-link icon="podcast" href="http://www.alnylam.com/web/assets/alnylam_podcast_ALN-APCprogram.mp3" type="(13.3MB mp3)"]Listen to our CMO discuss the hemophilia program[/spotlight-link]
[spotlight-link icon="presentation" href=http://www.alnylam.com/web/assets/ALNY-Hemophilia-Program-Overview.pdf type="(1.5MB PPT)"]View the slides [/spotlight-link]